Japan's Ministry of Health approves GSK's Omjjara (momelotinib) for myelofibrosis treatment.

GSK's Omjjara (momelotinib) has been approved by Japan's Ministry of Health, Labour and Welfare for treating myelofibrosis. It is a once-a-day, oral JAK1/JAK2 and ACVR1 inhibitor, based on data from phase III MOMENTUM and SIMPLIFY-1 trials. Approval applies to both newly diagnosed and previously treated patients, addressing key myelofibrosis symptoms like anaemia, constitutional symptoms, and splenomegaly.